Reported Earlier, Mirum Pharmaceuticals Prices $600M Convertible Senior Notes Due 2032 At 0.00%, Refinancing Portion Of 2029 Convertible Notes

Benzinga Newsdesk www.benzinga.com Neutral 92.0%